NUTRINEAL PD4 LIQUID

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

VALINE; LEUCINE; ISOLEUCINE; DL-METHIONINE; LYSINE (LYSINE MONOHYDROCHLORIDE); HISTIDINE; THREONINE; PHENYLALANINE; TRYPTOPHAN; ARGININE; ALANINE; PROLINE; GLYCINE; SERINE; TYROSINE; SODIUM CHLORIDE; SODIUM LACTATE; CALCIUM CHLORIDE; MAGNESIUM CHLORIDE

Tilgjengelig fra:

BAXTER CORPORATION

ATC-kode:

B05ZA

INN (International Name):

HEMODIALYTICS, CONCENTRATES

Dosering :

139.3MG; 102MG; 85MG; 85MG; 95.5MG; 71.4MG; 64.6MG; 57MG; 27MG; 107.1MG; 95.1MG; 59.5MG; 51MG; 51MG; 30MG; 538MG; 448MG; 18.4MG; 5.1MG

Legemiddelform:

LIQUID

Sammensetning:

VALINE 139.3MG; LEUCINE 102MG; ISOLEUCINE 85MG; DL-METHIONINE 85MG; LYSINE (LYSINE MONOHYDROCHLORIDE) 95.5MG; HISTIDINE 71.4MG; THREONINE 64.6MG; PHENYLALANINE 57MG; TRYPTOPHAN 27MG; ARGININE 107.1MG; ALANINE 95.1MG; PROLINE 59.5MG; GLYCINE 51MG; SERINE 51MG; TYROSINE 30MG; SODIUM CHLORIDE 538MG; SODIUM LACTATE 448MG; CALCIUM CHLORIDE 18.4MG; MAGNESIUM CHLORIDE 5.1MG

Administreringsrute:

HAEMODIALYSIS

Enheter i pakken:

2000/2500 ML

Resept typen:

Ethical

Terapeutisk område:

HEMODIALYSIS SOLUTION

Produkt oppsummering:

Active ingredient group (AIG) number: 1931508001; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2021-11-02

Preparatomtale

_ _
_Nutrineal_

_ PD4 (1.1% Amino Acid Peritoneal Dialysis Solution) _
_Page 1 of 31_
PRODUCT MONOGRAPH
NUTRINEAL™ PD4
1.1% Amino Acid Peritoneal Dialysis Solution
Peritoneal Dialysis Solution
Baxter Corporation
7125 Mississauga Road
Mississauga ON
L5N 0C2
www.baxter.ca
Date of Revision:
July 30, 2012
SUBMISSION CONTROL NO: 155366
_ _
_Nutrineal_

_ PD4 (1.1% Amino Acid Peritoneal Dialysis Solution) _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
.............................................